HealthcareNew regulator of prostate cancer metastasis discovered

New regulator of prostate cancer metastasis discovered

gene sequencing
Credit: Unsplash/CC0 Public Domain

A transcription factor normally associated with androgen receptor activity in prostate cancer has a newly discovered role in controlling lipid biosynthesis, according to a Northwestern Medicine study published in Nature Genetics.

The transcription factor, called HOXB13, is downregulated in late-stage , unleashing lipid biosynthesis and fueling , according to Jindan Yu, MD, Ph.D., professor of Medicine in the Division of Hematology and Oncology and senior author of the study.

“HOXB13 has mostly been studied as a gene activator, but our study shows its main function in transcriptional repression of lipid biosynthesis,” said Yu, who is also a professor of Biochemistry and Molecular Genetics and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

HOXB13 is a prostate-specific protein that is highly expressed in the prostate during development. It boosts (AR) function, which in turn helps grow.

In prostate cancer, androgen hormones fuel uncontrolled cell growth and AR inhibitor therapies are the mainstay of care. However, most metastatic prostate cancers will eventually develop resistance to AR therapy, with the tumors eventually reducing their dependency on androgen by becoming more like . Previous studies have shown that while HOXB13 has significant interaction with AR, their expression patterns do not match, with HOXB13 downregulating while AR upregulating as the cancer progresses.

“We thought something was missing about HOXB13, because HOXB13 and AR expression diverged,” Yu said.

In the current study, scientists investigated the non-AR functions of HOXB13, finding that the transcription factor has an entirely separate function in suppressing lipid biosynthesis, as part of the body’s normal defense against cancer. However, as prostate cancer cells lose their lineage and become treatment-resistant, they also lose expression of the prostate-specific HOXB13, resulting in a marked increase in lipid biosynthesis that can fuel cancer metastases.

“These cells forget who they are, which makes them AR-inhibitor resistant and can help the cancer spread,” Yu said.

More than 30% of treatment-resistant prostate cancer patients are HOXB13-negative and thus have elevated lipid biosynthesis in their cancers, so targeting this pathway could prove useful in prolonging survival for late-stage prostate cancer patients.

A drug called TVB-2640 that’s already in for breast and small-cell lung cancer may help: The drug inhibits an enzyme that’s critical for the biosynthesis pathway, restoring some of that normal inhibition that acts as a natural defense against cell proliferation and cancer.

“Now, we just need to identify the optimal population in which to use this drug,” Yu said.

The study also helped explain the curious case of G84E, a familial mutation in HOXB13 that increases risk for early-onset prostate cancer, but cancer severity was no different between patients with the G84E mutation and those without. The pathogenesis of the disease had previously been unknown, but the current study found the mutation disrupts inhibition, increasing levels of prostate-specific antigen (PSA), a biomarker sometimes used to screen for prostate cancer.

These findings raise the possibility that the observed increased risk of early-onset prostate cancer associated with G84E may be an epidemiological trick rather than a true pathogenic mutation at the time of diagnosis, according to Yu and co-author William Catalona, MD, professor of Urology and a pioneer in using PSA as a screening tool for prostate cancer.

“These patients have a family history, so they get screened for frequently and at a younger age,” Yu said. “This earlier diagnosis of G84E patients assures disease management at an earlier stage, which might have offered protection as it cures the disease before it reaches a treatment-resistant stage when G84E becomes pathogenic and promotes tumor metastasis.”

New genetic compound marker could help early diagnosis of aggressive prostate cancer

More information:
Xiaodong Lu et al, HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer, Nature Genetics (2022). DOI: 10.1038/s41588-022-01045-8

New regulator of prostate cancer metastasis discovered (2022, May 11)
retrieved 11 May 2022

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Original Source Link

Latest News

BitGo Announces Preliminary Deal To Acquire Prime Trust Custody Firm

BitGo Holdings, Inc., has announced its intention to acquire Prime Core Technologies, Inc., the parent company of Prime...

FirstFT: Trump says he has been indicted on criminal charges over handling of documents

Donald Trump said yesterday evening that he had been indicted on federal charges in connection with classified documents...

The Kakhovka Dam Collapse Is an Ecological Disaster | WIRED

While the world awaits evidence and further details about what exactly happened to the dam, there is no...

Scott Rawlings Of HOK: Face Time

Scott Rawlings, the national director of healthcare at HOK talks about his fortuitous career start, paying attention to...

SCOTUS Decides Jack Daniel’s v. VIP Products

The Supreme Court, with Justice Kagan writing for the unanimous Court, issued its decision in Jack Daniel's v....

Must Read

Bust Out Your Blindfolds! We’re Going Bird Boxing Again, Baby!

This trailer offers up a bit more than...

All About His Marriage To Sarah Williams – Hollywood Life

View gallery Joel McHale is a comedian known for...
- Advertisement -

You might also likeRELATED
Recommended to you